YOLFTbeta
Candel Therapeutics Inc

Candel Therapeutics Inc

CADL · NASDAQ · Healthcare / Biotechnology

6.20USD-2.19 (-26.10%)

Price History

Full chart

Market Stats

Previous Close8.39
Open5.33
Day Range5.20 – 6.63
52-Week Range4.35 – 14.00
Volume6.62M
Market Cap883.79M
P/E (TTM)0.00
Forward P/E43.48
EPS-1.51
Dividend Yield0.00%
Beta-0.47
50-Day Avg11.31
200-Day Avg7.79

About

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Paul-Peter Tak FOCIS, M.D., Ph.D.
  • Employees55
  • Headquarters117 Kendrick Street, Needham, MA, United States, 02494, USA
  • Websitehttps://www.candeltx.com

Leadership

  • Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.President, CEO & Director · b. 1960
  • Mr. Charles SchochSenior VP, CFO, Treasurer & Secretary · b. 1985
  • Dr. Francesca Barone M.D., Ph.D.Chief Scientific Officer · b. 1978
  • Dr. Seshu Tyagarajan Ph.D.Chief Technical & Development Officer · b. 1968
  • Ms. Ileen B. WinickChief People Officer
  • Ms. Susan Stewart J.D., L.L.M.Chief Regulatory Officer · b. 1961
  • Dr. William Nichols Garrett M.D., M.S.Chief Medical Officer · b. 1969
  • Mr. Mark SimsChief Commercial Officer

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue125.00K125.00K125.00K125.00K31.00K00
Growth (%)-0.00%0.00%0.00%-75.20%-100.00%-
Cost of Revenue6.61M-232.00K987.00K23.98M990.00K845.00K
Gross Profit125.00K125.00K125.00K125.00K-23.98M-990.00K-845.00K
Gross Margin100.00%100.00%100.00%100.00%-77354.84%--
Operating Expense9.16M13.94M25.85M34.80M14.41M32.38M47.42M
Operating Income-9.04M-13.81M-25.73M-34.67M-38.39M-33.37M-48.27M
Operating Margin-7229.60%-11048.00%-20580.80%-27739.20%-123841.94%--
EBITDA-8.42M-13.10M-35.84M-16.31M-34.38M-52.10M-35.22M
EBITDA Margin-6738.40%-10476.00%-28671.20%-13046.40%-110916.13%--
Net Income-8.24M-17.68M-36.12M-18.79M-37.94M-55.18M-38.18M
Net Income Margin-6592.00%-14144.00%-28899.20%-15035.20%-122383.87%--
R&D6.61M8.75M15.18M20.79M24.51M19.31M30.50M
R&D as % of Total Revenue5285.60%7003.20%12142.40%16629.60%79051.61%--
Interest Expense1.07M111.00K53.00K1.71M2.60M2.09M2.12M
Interest Expense % of Total Revenue856.00%88.80%42.40%1366.40%8370.97%--

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets45.90M38.28M89.20M78.52M41.20M106.87M125.19M
Total Liabilities53.94M61.84M25.07M30.80M28.46M40.54M73.27M
Total Equity-8.04M-23.56M64.14M47.71M12.74M66.33M51.92M
Cash5.18M35.05M82.64M70.06M35.41M102.65M119.73M
Total Debt420.00K946.00K560.00K22.80M22.76M13.47M1.90M
Net Debt-4.76M-34.11M-82.08M-47.26M-12.65M-89.18M-117.83M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.18M-9.07M-22.22M-31.42M-34.24M-27.02M-38.31M
Investing Cash Flow-35.74M38.45M-1.83M-1.30M-280.00K-16.00K-560.00K
Financing Cash Flow21.98M490.00K71.80M19.97M-121.00K94.28M56.10M
Capital Expenditure159.00K1.48M1.83M1.30M457.00K16.00K587.00K
Free Cash Flow-5.34M-10.55M-24.05M-32.72M-34.70M-27.04M-38.90M
FCF to OCF103.07%116.27%108.26%104.13%101.33%100.06%101.53%

Earnings

Report DateJun 2, 2021Sep 8, 2021Nov 12, 2021Mar 29, 2022May 12, 2022Aug 5, 2022Nov 10, 2022Mar 30, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 14, 2024Aug 13, 2024Nov 14, 2024Mar 13, 2025May 13, 2025Aug 14, 2025Nov 13, 2025Mar 26, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.35-0.12-0.29-0.32-0.31-0.43-0.36-0.31-0.35-0.37-0.19-0.16-0.28---0.30-0.24-0.17-0.16-0.25-0.33-0.22-0.30
EPS Actual-0.35-0.31-0.340.31-0.32-0.32-0.31-0.18-0.30-0.33-0.29-0.38-0.28-0.74-0.33-0.40-0.14-0.20-0.23-0.29-0.14-0.35-
Surprise0.74%-158.33%-17.24%196.88%-3.23%25.58%13.89%41.94%14.29%10.81%-52.63%-137.50%-0.57%---33.33%41.67%-17.65%-43.75%-17.01%57.58%-59.09%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market---Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap883.79M
Enterprise Value711.85M
Trailing P/E0.00
Forward P/E43.48
Price / Sales436.42
Price / Book6.85
EPS-1.51
Book Value1.66
Revenue (TTM)31.00K
Gross Profit (TTM)-23.07M
EBITDA-71.30M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-81.84%
Return on Assets-28.64%
Shares Outstanding76.52M
Shares Float60.22M
Beta-0.47
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 21.75
  • Strong Buy
    3

Ownership Breakdown

Institutions
67.63%
Insiders
14.65%
Retail / Other
17.72%

Top Institutional Holders

  • FMR Inc
    10.99M14.36%
  • RTW INVESTMENTS, LLC
    6.42M8.39%
  • Saturn V Capital Management LLC
    3.30M4.32%
  • BlackRock Inc
    3.11M4.06%
  • Portolan Capital Management, LLC
    2.89M3.78%
  • Vanguard Capital Management, LLC
    2.46M3.22%
  • Vestal Point Capital LP
    1.13M1.47%
  • Millennium Management LLC
    1.09M1.43%
  • Geode Capital Management, LLC
    1.04M1.35%
  • State Street Corp
    818.56K1.07%
  • Heights Capital Management Inc
    775.00K1.01%
  • Halter Ferguson Financial Inc
    772.46K1.01%

Top Fund Holders

  • Fidelity Select Biotechnology
    4.86M6.36%
  • State Street® SPDR® S&P® Biotech ETF
    2.14M2.79%
  • Fidelity Growth Company Fund
    2.11M2.76%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.97M2.57%
  • Strategic Advisers U.S. Total Stock
    1.91M2.50%
  • iShares Russell 2000 ETF
    1.63M2.13%
  • Fidelity Small Cap Index
    687.61K0.90%
  • Fidelity Growth Company K6
    604.71K0.79%